Cyclophosphamide induced haemorrhagic myocarditis-pericarditis: a rare but lethal complication in the setting of allogeneic stem cell transplantation
- PMID: 35760892
- DOI: 10.1038/s41409-022-01745-z
Cyclophosphamide induced haemorrhagic myocarditis-pericarditis: a rare but lethal complication in the setting of allogeneic stem cell transplantation
Similar articles
-
Fatal haemorrhagic myocarditis secondary to cyclophosphamide therapy.Br J Radiol. 2000 Oct;73(874):1112-4. doi: 10.1259/bjr.73.874.11271907. Br J Radiol. 2000. PMID: 11271907
-
Myopericarditis caused by cyclophosphamide used to mobilize peripheral blood stem cells in a myeloma patient with renal failure.Bone Marrow Transplant. 2000 Sep;26(6):685-8. doi: 10.1038/sj.bmt.1702592. Bone Marrow Transplant. 2000. PMID: 11041571
-
High-dose cyclophosphamide therapy associated with diffuse alveolar hemorrhage after allogeneic hematopoietic stem cell transplantation.Respiration. 2013;86(6):453-61. doi: 10.1159/000345592. Epub 2012 Dec 29. Respiration. 2013. PMID: 23295208
-
Myocarditis, pericarditis and cardiomyopathy in patients treated with clozapine.J Clin Pharm Ther. 2005 Feb;30(1):91-6. doi: 10.1111/j.1365-2710.2004.00616_1.x. J Clin Pharm Ther. 2005. PMID: 15659009 Review.
-
Reports of myocarditis and pericarditis following mRNA COVID-19 vaccination: a systematic review of spontaneously reported data from the UK, Europe and the USA and of the scientific literature.BMJ Open. 2022 May 25;12(5):e059223. doi: 10.1136/bmjopen-2021-059223. BMJ Open. 2022. PMID: 35613761 Free PMC article.
Cited by
-
Post-transplant cyclophosphamide-induced cardiotoxicity: A comprehensive review.J Cardiovasc Thorac Res. 2024;16(4):211-221. doi: 10.34172/jcvtr.33230. Epub 2024 Dec 23. J Cardiovasc Thorac Res. 2024. PMID: 40027370 Free PMC article. Review.
References
-
- Friedman OM, Wodinsky I, Myles A. Cyclophosphamide (NSC-26271)-related phosphoramide mustards- recent advances and historical perspective. Cancer Treat Rep. 1976;60:337–46. - PubMed
-
- Kohn FR, Sladek NE. Aldehyde dehydrogenase activity as the basis for the relative insensitivity of murine pluripotent hematopoietic stem cells to oxazaphosphorines. Biochem Pharm. 1985;34:3465–71. - DOI
-
- Goldberg MA, Antin JH, Guinan EC, Rappeport JM. Cyclophosphamide cardiotoxicity: an analysis of dosing as a risk factor. Blood. 1986;68:1114–8. - DOI
-
- Yeh J, Whited L, Saliba RM, Rondon G, Banchs J, Shpall E, et al. Cardiac toxicity after matched allogeneic hematopoietic cell transplant in the posttransplant cyclophosphamide era. Blood Adv. 2021;5:5599–607. - DOI
-
- Appelbaum F, Strauchen J, Graw R, Savage D, Kent K, Ferrans V, et al. Acute lethal carditis caused by high-dose combination chemotherapy: a unique clinical and pathological entity. Orig Publ. 1976;307:58–62.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical